Kineta Inc.

Quick facts

Phase 1 pipeline

• KVA12123 - Dose Escalation
• KVA12123 - Dose Expansion
• KVA12123 Plus Pembrolizumab - Dose Escalation
• KVA12123 Plus Pembrolizumab - Dose Expansion
  Combination therapy pairing KVA12123 with pembrolizumab, a PD-1 checkpoint inhibitor that enhances T-cell mediated anti-tumor immunity.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kineta Inc. portfolio CI brief
• Kineta Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies